(BLTE) Belite Bio - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US07782B1044
BLTE: Drugs, Therapies, Medicines, Treatments, Pills, Tablets
Belite Bio Inc ADR (NASDAQ:BLTE) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for retinal degenerative eye diseases with significant unmet medical needs. Their lead product candidate, LBS-008 (Tinlarebant), is an orally administered once-daily tablet designed to maintain retinal tissue health and integrity, primarily targeting autosomal recessive Stargardt disease and geographic atrophy. This approach addresses a critical gap in treatment options for these conditions, which currently have limited therapeutic interventions.
Additionally, Belite Bio is advancing LBS-009, an anti-retinol binding protein 4 (RBP4) oral therapy, currently in preclinical development. This candidate targets liver diseases, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and type 2 diabetes. The companys pipeline reflects a strategic focus on addressing both rare and prevalent diseases, leveraging its expertise in retinal and metabolic disorders.
Founded in 2016 and headquartered in San Diego, California, Belite Bio operates as a subsidiary of Lin Bioscience International Ltd. The companys market capitalization stands at approximately $1.88 billion USD, with a price-to-book ratio of 16.75, reflecting investor confidence in its growth potential. For more information, visit their website at https://www.belitebio.com.
Additional Sources for BLTE Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
BLTE Stock Overview
| Market Cap in USD | 1,837m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2022-04-29 |
BLTE Stock Ratings
| Growth 5y | 69.6% |
| Fundamental | - |
| Dividend | 0.0% |
| Rel. Strength | 72.2 |
| Analysts | 4.6/5 |
| Fair Price Momentum | 70.38 USD |
| Fair Price DCF | - |
BLTE Dividends
No Dividends PaidBLTE Growth Ratios
| Growth Correlation 3m | 58% |
| Growth Correlation 12m | 81.4% |
| Growth Correlation 5y | 83.4% |
| CAGR 5y | 75.98% |
| CAGR/Max DD 5y | 1.02 |
| Sharpe Ratio 12m | 0.02 |
| Alpha | 26.20 |
| Beta | -1.544 |
| Volatility | 38.63% |
| Current Volume | 53.1k |
| Average Volume 20d | 30.2k |
As of April 09, 2025, the stock is trading at USD 55.67 with a total of 53,144 shares traded.
Over the past week, the price has changed by -15.93%, over one month by -11.90%, over three months by -5.26% and over the past year by +39.24%.
Yes. Based on ValueRay Analyses, Belite Bio (NASDAQ:BLTE) is currently (April 2025) a good stock to buy. It has a ValueRay Growth Rating of 69.55 and therefor a clear technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BLTE as of April 2025 is 70.38. This means that BLTE is currently undervalued and has a potential upside of +26.42% (Margin of Safety).
Belite Bio has received a consensus analysts rating of 4.60. Therefor, it is recommend to buy BLTE.
- Strong Buy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, BLTE Belite Bio will be worth about 76 in April 2026. The stock is currently trading at 55.67. This means that the stock has a potential upside of +36.54%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 85 | 52.7% |
| Analysts Target Price | 79.3 | 42.4% |
| ValueRay Target Price | 76 | 36.5% |